Terumo Corp. (4543)

Currency in JPY
2,244.5
+20.0(+0.90%)
Closed·
4543 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,213.52,267.5
52 wk Range
1,900.02,818.0
Key Statistics
Bid/Ask
2,243.00 / 2,245.00
Prev. Close
2,224.5
Open
2,218
Day's Range
2,213.5-2,267.5
52 wk Range
1,900-2,818
Volume
3.21M
Average Volume (3m)
5.85M
1-Year Change
-14.4464%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4543 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,977.7
Upside
+32.67%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Terumo Corp. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

11 Buy
3 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2,977.7
(+32.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy2,700.00+20.29%2,500.00MaintainJun 22, 2026
Citi
Buy3,300.00+47.03%3,000.00MaintainMay 27, 2026
JPMorgan
Buy2,500.00+11.38%2,700.00MaintainApr 08, 2026
Morgan Stanley
Hold2,400.00+6.93%2,800.00MaintainMar 18, 2026
Nomura/Instinet
Hold2,100.00-6.44%2,300.00MaintainFeb 24, 2026

Terumo Corp. Earnings Call Summary for Q4/2026

  • Terumo Q4 2025 EPS of 17.87 JPY beat forecast by 19.77%; revenue of 300.32B JPY exceeded estimates by 4.24%, driving 18.08% stock surge
  • Operating profit hit record 176.3B JPY; adjusted operating profit reached 219.4B JPY despite tariff impacts and one-time expenses
  • Strong North America demand and successful OrganOx acquisition integration drove fifth consecutive year of record-breaking sales
  • FY 2026 guidance includes dividend increase to 36 JPY per share; absence of one-time expenses expected to boost profit growth
  • Key risks include supply chain disruptions, tariff pressures, and competitive challenges in neurovascular and organ preservation markets
Last Updated: 2026-05-20, 03:44 p/m
Read Full Transcript

Earnings

Latest Release
May 15, 2026
EPS / Forecast
17.87 / 14.92
Revenue / Forecast
300.32B / 288.1B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 92.12%
Dividend Yield
1.35%
Industry Median 1.46%
Annualized payout
30.00
Paid unevenly
5-Years Growth
+14.87%
Growth Streak

4543 Income Statement

Compare 4543 to Peers and Sector

Metrics to compare
4543
Peers
Sector
Relationship
P/E Ratio
24.4x22.4x−0.4x
PEG Ratio
1.450.380.00
Price/Book
2.1x2.2x2.6x
Price / LTM Sales
2.9x1.7x3.0x
Upside (Analyst Target)
39.4%15.7%58.1%
Fair Value Upside
Unlock23.6%8.2%Unlock

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.

Employees
30591
Market
Japan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
667.00M45.22%1.48T
Other Institutional Investors
376.46M25.52%837.44B
Public Companies & Retail Investors
431.62M29.26%960.14B
Total
1.48B100.00%3.28T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nomura Asset Management Co., Ltd.8.81%129,978,400289,136,951
BlackRock, Inc.7.34%108,197,340240,684,983

People Also Watch

26,425.0
4062
+7.59%
4,063.0
6762
+3.94%
3,672.0
6971
-0.22%
32,170.0
6857
+1.35%

FAQ

What Is the Terumo Corp. (4543) Stock Price Today?

The Terumo Corp. stock price today is 2,244.5 JPY.

What Stock Exchange Does Terumo Corp. Trade On?

Terumo Corp. is listed and trades on the Tokyo Stock Exchange.

What Is the Stock Symbol for Terumo Corp.?

The stock symbol for Terumo Corp. is "4543."

Does Terumo Corp. Pay Dividends? What’s The Current Dividend Yield?

The Terumo Corp. dividend yield is 1.33%.

What Is the Terumo Corp. Market Cap?

As of today, Terumo Corp. market cap is 3.31T JPY.

What Is Terumo Corp.'s Earnings Per Share (TTM)?

The Terumo Corp. EPS (TTM) is 92.1.

When Is the Next Terumo Corp. Earnings Date?

Terumo Corp. will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is 4543 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Terumo Corp. Stock Split?

Terumo Corp. has split 3 times.

How Many Employees Does Terumo Corp. Have?

Terumo Corp. has 30591 employees.

What is the current trading status of Terumo Corp. (4543)?

As of Jun 22, 2026, Terumo Corp. (4543) is trading at a price of 2,244.5 JPY, with a previous close of 2,224.5 JPY. The stock has fluctuated within a day range of 2,213.5 JPY to 2,267.5 JPY, while its 52-week range spans from 1,900.0 JPY to 2,818.0 JPY.

What Is Terumo Corp. (4543) Price Target According to Analysts?

The average 12-month price target for Terumo Corp. is 2,977.7 JPY, with a high estimate of 3700 JPY and a low estimate of 2100 JPY. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +32.67% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.